Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00191607 · ClinicalTrials.gov registry record · Phase 3
A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.
A Phase 3 study of Ovarian Neoplasms and Peritoneal Neoplasms, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 162
- Enrollment target
- 1
- Study location
NCT00191607 is a Phase 3 study of Ovarian Neoplasms and Peritoneal Neoplasms that has completed, run by Eli Lilly and Company. The registered enrollment target is 162 participants, below the 364-participant average among 38 other Ovarian Neoplasms trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00191607, a Phase 3 study of Ovarian Neoplasms and Peritoneal Neoplasms, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 162 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial compares two chemotherapy agents for the treatment of recurrent ovarian, fallopian or primary peritoneal cancer in patients that have received and are no longer responding to Platinum based treatment. The purpose of this trial is to compare progression free survival between gemcitabine and liposomal doxorubicin. Progression free survival (PFS) is defined as the period from study entry until disease progression
Conditions Studied
Interventions
- DRUG Gemcitabine
- DRUG liposomal doxorubicin
Study Locations (1)
Missouri
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2002-07 |
| Est. Completion | 2005-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00191607
The ClinicalTrials.gov registry entry for NCT00191607 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 364-participant average among 38 other Ovarian Neoplasms trials with a reported enrollment target (55% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Ovarian Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Gemcitabine is the first listed.
NCT00191607 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT00191607 about?
NCT00191607 is a clinical study titled "A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.". This trial compares two chemotherapy agents for the treatment of recurrent ovarian, fallopian or primary peritoneal cancer in patients that have received and are no longer responding to Platinum based treatment. The purpose of this trial is to compare progression free survival between gemcitabine an...
What is the current status of trial NCT00191607?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 162 participants. The study started on 2002-07. Estimated completion is 2005-11.
What conditions does trial NCT00191607 study?
This clinical trial studies the following conditions: Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Pelvic Neoplasms.
What interventions are being tested in trial NCT00191607?
The interventions under investigation include: Gemcitabine (DRUG), liposomal doxorubicin (DRUG).
Who is sponsoring clinical trial NCT00191607?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00191607 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
RECRUITING · Phase 3
-
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
RECRUITING · Phase 3
-
A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
ACTIVE NOT RECRUITING · Phase 3
-
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
ACTIVE NOT RECRUITING · Phase 3
-
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.